The study [26] included both NMIBC (40% of the patient population) and muscle-invasive BC (stage T2 or higher; 60% of the patient population), positive CREBBP expression was noted in 86% of patients (47/55), which was significantly higher than that in ours (35.4%). Here, CREBBP is linked to breast cancer.